Next Article in Journal
Structural Basis of Targeting the Exportin CRM1 in Cancer
Next Article in Special Issue
Intracellular Mono-ADP-Ribosylation in Signaling and Disease
Previous Article in Journal
Specialized Cilia in Mammalian Sensory Systems
Previous Article in Special Issue
Mitochondrial Impairment May Increase Cellular NAD(P)H: Resazurin Oxidoreductase Activity, Perturbing the NAD(P)H-Based Viability Assays

NAD+-Metabolizing Ectoenzymes in Remodeling Tumor–Host Interactions: The Human Myeloma Model

Laboratory of Immunogenetics, Department of Medical Sciences, University of Torino, Torino 10126, Italy
CeRMS, University of Torino, Torino 10126, Italy
Laboratory of Oncology, Istituto Giannina Gaslini, Genova 16148, Italy
Myeloma Unit, Department of Clinical and Experimental Medicine, University of Parma, Parma 43126, Italy
Antibody & Vaccine Group, Cancer Sciences Unit, Faculty of Medicine, University of Southampton, Southampton General Hospital, Southampton SO16 6YD, UK
School of Biosciences and Veterinary Medicine, University of Camerino, Camerino 62032, Italy
Janssen Research & Development, LLC, Springhouse, PA 19477, USA
Authors to whom correspondence should be addressed.
Academic Editor: Ross Grant
Cells 2015, 4(3), 520-537;
Received: 4 August 2015 / Revised: 9 September 2015 / Accepted: 14 September 2015 / Published: 17 September 2015
(This article belongs to the Special Issue NAD+ Metabolism and Signaling)
Nicotinamide adenine dinucleotide (NAD+) is an essential co-enzyme reported to operate both intra- and extracellularly. In the extracellular space, NAD+ can elicit signals by binding purinergic P2 receptors or it can serve as the substrate for a chain of ectoenzymes. As a substrate, it is converted to adenosine (ADO) and then taken up by the cells, where it is transformed and reincorporated into the intracellular nucleotide pool. Nucleotide-nucleoside conversion is regulated by membrane-bound ectoenzymes. CD38, the main mammalian enzyme that hydrolyzes NAD+, belongs to the ectoenzymatic network generating intracellular Ca2+-active metabolites. Within this general framework, the extracellular conversion of NAD+ can vary significantly according to the tissue environment or pathological conditions. Accumulating evidence suggests that tumor cells exploit such a network for migrating and homing to protected areas and, even more importantly, for evading the immune response. We report on the experience of this lab to exploit human multiple myeloma (MM), a neoplastic expansion of plasma cells, as a model to investigate these issues. MM cells express high levels of surface CD38 and grow in an environment prevalently represented by closed niches hosted in the bone marrow (BM). An original approach of this study derives from the recent use of the clinical availability of therapeutic anti-CD38 monoclonal antibodies (mAbs) in perturbing tumor viability and enzymatic functions in conditions mimicking what happens in vivo. View Full-Text
Keywords: NAD+; CD38; ectoenzymes; adenosine; multiple myeloma; Daratumumab NAD+; CD38; ectoenzymes; adenosine; multiple myeloma; Daratumumab
Show Figures

Figure 1

MDPI and ACS Style

Horenstein, A.L.; Chillemi, A.; Quarona, V.; Zito, A.; Roato, I.; Morandi, F.; Marimpietri, D.; Bolzoni, M.; Toscani, D.; Oldham, R.J.; Cuccioloni, M.; Sasser, A.K.; Pistoia, V.; Giuliani, N.; Malavasi, F. NAD+-Metabolizing Ectoenzymes in Remodeling Tumor–Host Interactions: The Human Myeloma Model. Cells 2015, 4, 520-537.

AMA Style

Horenstein AL, Chillemi A, Quarona V, Zito A, Roato I, Morandi F, Marimpietri D, Bolzoni M, Toscani D, Oldham RJ, Cuccioloni M, Sasser AK, Pistoia V, Giuliani N, Malavasi F. NAD+-Metabolizing Ectoenzymes in Remodeling Tumor–Host Interactions: The Human Myeloma Model. Cells. 2015; 4(3):520-537.

Chicago/Turabian Style

Horenstein, Alberto L., Antonella Chillemi, Valeria Quarona, Andrea Zito, Ilaria Roato, Fabio Morandi, Danilo Marimpietri, Marina Bolzoni, Denise Toscani, Robert J. Oldham, Massimiliano Cuccioloni, A. Kate Sasser, Vito Pistoia, Nicola Giuliani, and Fabio Malavasi. 2015. "NAD+-Metabolizing Ectoenzymes in Remodeling Tumor–Host Interactions: The Human Myeloma Model" Cells 4, no. 3: 520-537.

Find Other Styles

Article Access Map by Country/Region

Only visits after 24 November 2015 are recorded.
Back to TopTop